Lille ALS Center

CHU Lille

The multidisciplinary specialists’ team of the Lille ALS Center aims to minimize ALS morbidity and optimize quality of life. Using a translational approach, we develop new therapeutic concepts for neurodegenerative diseases and especially for ALS.

 

LilleALSCenter_Logo
CHU Lille

Our ALS Center provides multidisciplinary care to minimize symptoms and optimize quality of life. To achieve this, multiple specialists coordinate patient care by monitoring disease progression, anticipating complications, providing technological tools, adapting the living environment and providing social support to help people stay at home. We have a lot of expertise in early planning of patient care and coordination of care for patients at home (including via teleconsultation). We also provide information about treatments and conduct ethical assessments with partners from the health sector, the medical social sector, the hospital sector and home care.

We take a translational approach in our research, with activities ranging from cell and mouse models to the assessment of large multicenter cohorts of patients (PULSE study; ClinicalTrials.gov: NCT02360891). We are currently developing two new treatment strategies: 1) Conservative iron chelation (FAIR ALS-II trial; ClinicalTrials.gov: NCT0329293069) and 2) a novel biotherapy based on the physiological healing system in the platelets (GIFT project). The PULSE project, a collaboration of 17 French ALS centers and supported by the Patient Association (ARSLA), is led by Professor David Devos. He is also the principal investigator of the FAIR ALS-II trial.

Contact
Location
Centre SLA, Neurologie, Hopital Salengro, CHU, 59037, lille cedex

Specialists

Veronique Danel-Brunaud

Consultant Neurologist and Head of ALS Center

Dr Veronique Danel-Brunaud is head of the Lille ALS Center. She is […]

Veronique Danel-Brunaud
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Active
Phase iii

ADORE trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more